TELL ME MORE ABOUT
THIS STUDY FOR HYPERTENSION
A phase 3 global, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of an investigational medicine in addition to standard of care in reducing major adverse cardiovascular events in adult patients with hypertension not adequately controlled and with either established cardiovascular disease or high risk for cardiovascular disease
Study Location(s): Evansville, IN
High blood pressure is a common condition that affects the body’s arteries. It’s also called hypertension. If you have high blood pressure, the force of the blood pushing against the artery walls is consistently too high. The heart has to work harder to pump blood. The excessive pressure on the artery walls caused by high blood pressure can damage blood vessels and body organs. The higher the blood pressure and the longer it goes uncontrolled, the greater the damage. (Mayo Clinic)
Hypertension affects an estimated 33% of adults 30-79 years worldwide and is a major cause of premature death worldwide. (World Health Organization)
Resistant hypertension is blood pressure that’s higher than normal even though you’re taking at least three different medicines for it at once. Compared to people with high (but regulated) blood pressure, people with hard-to-treat, resistant hypertension have a higher risk of stroke, kidney disease, and heart failure. (Clevland Clinic)
About this study
The goal of this study is to assess the ability of an investigational medication to reduce the risk of CV death, non-fatal MI, non-fatal stroke, or HF events in adults with hypertension and with established CVD or high risk for CVD.
There is no cost to participate. Volunteers receive no cost investigational medicine and no cost health exams. Insurance is not required to participate. Reimbursement for time and travel up to TBD.